The Cross-Border Biotech Blog

Q4 2016_Part1-01

For the analysis of the 2016 share price performance for the Canadian healthcare sector, there were 115 companies starting 2016 with share prices of $0.10 or higher. Twelve of these companies were no longer in the sector by the end of 2016, with six lost through acquisition/merger transactions. For the remaining 103 companies, the sector […]

read more


Q3 2016_Part3-01

Tier 2 Canadian Healthcare Companies – better performance than the Tier 1 companies In this blog, I am going to comment on the Q3 and 9-month 2016 share price performance of the group of 57 companies with share prices of between $0.10 and $0.99 to start 2016 (DiagnoCure is not included). Advancers outnumbered decliners by […]

read more


Q3 2016_Part2-01

Tier 1 Canadian Healthcare Companies – a very healthy bounce back In this blog, I am going to comment on the Q3 and 9-month performances of the group of 54 companies with share prices of $1.00 or more to start 2016 (Stellar Biotechnologies, Prism Medical and Transition Therapeutics dropped from assessment). Advancers outnumbered decliners by […]

read more


Q3 2016_Part1-01

Improved, positive performance in Q3 Overall, Q3 2016 share price performance in the sector was much better than in Q2 for the companies starting 2015 with share prices of $0.10 or higher. Two more companies have been deleted from the analysis in Q3 – Transition Therapeutics was acquired by OPKO Health and Prism Medical was […]

read more


RGB_bb_logo - black background

TORONTO, September 6, 2016 – Bloom Burton & Co. Limited (“Bloom Burton”), Canada’s leading healthcare-specialized investment banking firm, is pleased to announce the appointment of Shawn Aspden as Managing Director of the firm. Mr. Aspden, CFA®, is a highly respected 20-year veteran of the Canadian capital markets, having most recently served as Vice Chairman and […]

read more


Human POC

Check out the CTI Life Sciences Fund’s Janelle Anderson’s interview of Brian Bloom on the Human Proof Of Concept podcast by clicking on the image below.

read more


Screen Shot 2016-08-16 at 8.52.51 AM

Click on the link above to see a profile of the 5th Bloom Burton Healthcare Investor Conference on Business Television.

read more


Q2 2016_Part2-01

Tier 1 Canadian Healthcare Companies – Flat with less volatility In this blog, I am going to comment on the Q2 and H1 performances of the group of 56 companies with share prices of $1.00 or more to start 2016 (Stellar Biotechnologies dropped from assessment). Advancers slightly outnumbered decliners by 29 to 27 Average and […]

read more


Q2 2016_Part1-01

Overall, Q2 2016 share price performance in the sector was slightly positive for the companies starting 2015 with share prices of $0.10 or higher. Two companies have been deleted from the analysis – DiagnoCure is undergoing voluntary liquidation and dissolution and Stellar Biotechnologies delisted from the TSX and no longer has any Canadian link. Advancers […]

read more


SharePricePerformance_ViolatileandNegagiveinQ1_Part3-01

Tier 2 Canadian Healthcare Companies – negative but no panic (same as Tier 1) In this blog, I am going to comment on the Q1 2016 share price performance of the group of 61 companies with share prices of between $0.10 and $0.99 to start 2016. Decliners outnumbered advancers by 36 to 25 (better than […]

read more